Head to Head Contrast: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. Tectonic Therapeutic (NASDAQ:TECX)

Fresh Tracks Therapeutics (NASDAQ:FRTX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Risk and Volatility

Fresh Tracks Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500.

Earnings & Valuation

This table compares Fresh Tracks Therapeutics and Tectonic Therapeutic”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresh Tracks Therapeutics	$8.01 million	0.69	-$5.69 million	($1.41)	-0.66
Tectonic Therapeutic	N/A	N/A	$12.16 million	($5.89)	-5.35

Tectonic Therapeutic has lower revenue, but higher earnings than Fresh Tracks Therapeutics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fresh Tracks Therapeutics and Tectonic Therapeutic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresh Tracks Therapeutics	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-35.53%	-31.97%

Institutional and Insider Ownership

25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Fresh Tracks Therapeutics and Tectonic Therapeutic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresh Tracks Therapeutics	0	0	0	0	0.00
Tectonic Therapeutic	0	0	5	1	3.17

Tectonic Therapeutic has a consensus price target of $80.50, suggesting a potential upside of 155.64%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Fresh Tracks Therapeutics.

Summary

Tectonic Therapeutic beats Fresh Tracks Therapeutics on 8 of the 13 factors compared between the two stocks.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.